Development of a robust QSAR model to predict the affinity of pyrrolidine analogs for dipeptidyl peptidase IV (DPP- IV)

By Paliwal Sarvesh   Seth Deepika   Yadav Divya   Yadav Rakesh   Paliwal Shailendra  

Journal of Enzyme Inhibition and Medicinal Chemistry, Vol. 26, Iss. 1, 2011-02 ,pp. : 129-140

Informa Healthcare

Access to resources Recommend Favorite

Dipeptidyl Peptidase IV (DP IV/CD26) mRNA Expression in PWM-Stimulated T-Cells Is Suppressed by Specific DP IV Inhibition, an Effect Mediated by TGF-β₁

By Arndt M.   Lendeckel U.   Spiess A.   Faust J.   Neubert K.   Reinhold D.   Ansorge S.  

Biochemical and Biophysical Research Communications, Vol. 274, Iss. 2, 2000-08 ,pp. : 410-414

Elsevier

Access to resources Recommend Favorite

Reduced Cell Surface Expression of a Mutated Dipeptidyl Peptidase IV (DPP IV/CD26) Correlates with the Generation of a β Strand in Its C-Terminal Domain

By David F.   Baricault L.   Sapin C.   Gallet X.   Marguet D.   Thomas-Soumarmon A.   Trugnan G.  

Biochemical and Biophysical Research Communications, Vol. 222, Iss. 3, 1996-05 ,pp. : 833-838

Elsevier

Access to resources Recommend Favorite

Dipeptidyl peptidase IV inhibition as an approach to the treatment and prevention of type 2 diabetes: a historical perspective

By Deacon C.F.   Holst J.J.  

Biochemical and Biophysical Research Communications, Vol. 294, Iss. 1, 2002-05 ,pp. : 1-4

Elsevier

Access to resources Recommend Favorite

Rebuttal to Deacon and Holst: “Metformin effects on dipeptidyl peptidase IV degradation of glucagon-like peptide-1” versus “Dipeptidyl peptidase inhibition as an approach to the treatment and prevention of type 2 diabetes: a historical perspective”

By Demuth H-U.   Hinke S.A.   Pederson R.A.   McIntosh C.H.S.  

Biochemical and Biophysical Research Communications, Vol. 296, Iss. 2, 2002-08 ,pp. : 229-232

Elsevier

Access to resources Recommend Favorite